Microvast Holdings announces departure of chief financial officer
Investing.com - William Blair reiterated its outperform rating on CRISPR Therapeutics (NASDAQ:CRSP) on Thursday, citing competitive clinical data for the company’s CTX310 program. The $4.3 billion biotech company has shown strong momentum, with a 16% return over the past six months, according to InvestingPro data.
The firm noted that CTX310’s LDL-C reduction results appear competitive with similar treatments from Arrowhead (NASDAQ:ARWR) and Regeneron (NASDAQ:REGN), specifically ARO-ANG3 and Evkeeza. William Blair highlighted that early triglyceride reductions could potentially set "a new bar in the space." With an overall Financial Health Score of "FAIR" from InvestingPro, CRISPR maintains strong liquidity with a current ratio of 15.6.
While acknowledging disappointment regarding a delay in the CTX320 readout, William Blair supported the decision as it will enable CRISPR Therapeutics to release a more comprehensive dataset. The firm also noted that the Phase III HORIZON study could provide additional context for the data.
William Blair expressed interest in future data releases from the CTX310 program, which could offer insights into durability, Phase II dosing decisions, and potential accelerated approval pathways for the treatment.
The firm suggested that CRISPR’s cardiovascular programs could become "near-term business development targets," referencing Eli Lilly’s (NYSE:LLY) recent acquisition of Verve Therapeutics (NASDAQ:VERV) as a comparable industry development.
In other recent news, CRISPR Therapeutics reported promising Phase 1 clinical data for its cholesterol drug CTX310, which showed significant reductions in triglycerides and LDL cholesterol levels. The company highlighted dose-dependent decreases with peak reductions reaching up to 82% for triglycerides and up to 86% for LDL cholesterol, alongside a well-tolerated safety profile. Additionally, CRISPR Therapeutics announced a strategic partnership with Sirius Therapeutics to develop SRSD107, a novel siRNA therapy targeting Factor XI for thromboembolic disorders. This collaboration includes an upfront payment of $25 million in cash and $70 million in equity, with plans for a Phase 2 trial to assess the drug’s efficacy in preventing venous thromboembolism. Citizens JMP reiterated its Market Outperform rating and $86 price target for CRISPR Therapeutics, citing progress in its in-vivo therapeutic programs and the potential for growth beyond its current valuation. At its Annual General Meeting, CRISPR Therapeutics’ shareholders approved key proposals, including amendments to the Articles of Association and the election of board members. The company also announced a delay in data for its CTX320 program, now expected in the first half of 2026, to incorporate emerging insights. These developments reflect CRISPR Therapeutics’ strategic expansion in gene-based therapies and continued innovation in addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.